WO2001059448A1 - Procede de criblage d'un agent antiandrogene - Google Patents
Procede de criblage d'un agent antiandrogene Download PDFInfo
- Publication number
- WO2001059448A1 WO2001059448A1 PCT/JP2001/000936 JP0100936W WO0159448A1 WO 2001059448 A1 WO2001059448 A1 WO 2001059448A1 JP 0100936 W JP0100936 W JP 0100936W WO 0159448 A1 WO0159448 A1 WO 0159448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclin
- androgen receptor
- compound
- screening
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Definitions
- a method for screening a compound that inhibits the interaction between cyclin E and an androgen receptor comprising:
- the present invention provides a method for screening a compound that inhibits the interaction between cyclin E and AR.
- One embodiment of the screening method of the present invention is a method using inhibition of the binding activity between cyclin E and AR as an index.
- One embodiment of this method comprises: (a) contacting cyclin E with an androgen receptor in the presence of a test sample; (b) detecting the binding of the cyclin E to the androgen receptor; and (C) Selecting a compound that reduces the binding as compared to the case where detection is performed in the absence of a test sample (control).
- the cyclins E and AR used for this screening may be recombinant proteins or naturally-occurring proteins.
- the “cyclin E” is not limited to the complete protein of cyclin E, but includes a partial peptide thereof as long as it has an activity of binding to AR.
- the “AR” is not limited to a complete protein, but includes a partial peptide thereof as long as it has a binding activity to cyclin E.
- peptides containing the AB domain of AR can be suitably used for this screening.
- Cyclin I or AR may be labeled as appropriate.
- the labeling method include a method using the binding property of biotin and avidin, a method using an antibody that specifically binds to cyclin ⁇ AR or a peptide or polypeptide (eg, GST or the like) fused thereto, and a radioisotope. And a method using fluorescence. In the pull-down assay, these proteins can be contacted in vivo using purified cyclin II and AR, but can also be contacted in vivo.
- test sample is contacted with cells expressing endogenous cyclin ⁇ and androgen receptor, instead of cells into which vectors expressing exogenous cyclin ⁇ and AR have been introduced.
- An analysis can also be performed.
- a biosensor utilizing the surface plasmon resonance phenomenon can be used as a means for detecting or measuring the bound compound.
- a biosensor using the surface plasmon resonance phenomenon can observe the interaction between cyclin E and AR in real time as a surface plasmon resonance signal without labeling (for example, BIAcore, Pharmacia). Therefore, it is possible to evaluate the binding between cyclin E and AR by using a biosensor such as BIAcore ⁇ o
- a compound that inhibits the interaction between cyclin E and AR of the present invention, or a pharmaceutically acceptable salt thereof, or a prodrug thereof is used in a human or mammal, for example, mouse, rat, guinea pig, egret, chicken, and cat.
- a human or mammal for example, mouse, rat, guinea pig, egret, chicken, and cat.
- these compounds may be formulated by known pharmaceutical methods in addition to directly administering to the patient. Administration can also be performed.
- Figure 4 is a diagram and a photograph showing the location of the cyclin E binding domain within the AR AB domain.
- pGRE-tk-CAT was used for GR and pPRE-tk-CAT was used for ⁇ for reporter plasmid. Furthermore, ER expression base Kuta one, and using a reporter plus Mi de as pBL- CAT8 + / ERE, estrogen -; was also investigated (17 estradiol? 10- 8 M) Effect of.
- Immunoprecipitation was performed by incubating the cell lysate with anti-cyclin E antibody (Sun-Cultures Biotechnology, Inc.) followed by protein A agarose beads (Berlinga-I, Mannheim, Mannheim, Germany) at 4 ° C. Incubation was carried out. One hour later, the beads were collected by gentle centrifugation and boiled in Laemmli buffer. Samples were separated on a 10% SDS polyacrylamide gel and transferred to a nitrocellulose membrane. After blocking with PBS containing 5% milk and 0.1% zinc 20, a polyclonal antibody against human AR (Sunshine Cruz Biotechnology) and peroxidase-conjugated goat anti-mouse IgG Detected the protein. The broth is washed with PBS containing 0.1% zinc 20, and the enhanced chemiluminescence (ECL) reaction is performed. (Massham).
- ECL enhanced chemiluminescence
- GST-AR (AB) protein or various deletion mutant proteins were mixed with cyclin E translated in the mouth .
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001230606A AU2001230606A1 (en) | 2000-02-10 | 2001-02-09 | Method of screening antiandrogen agent |
EP01902829A EP1258727A4 (en) | 2000-02-10 | 2001-02-09 | PROCESS FOR SCREENING TO ANTI-ANDROGENAGENSIA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000038151 | 2000-02-10 | ||
JP2000-38151 | 2000-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001059448A1 true WO2001059448A1 (fr) | 2001-08-16 |
Family
ID=18561932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000936 WO2001059448A1 (fr) | 2000-02-10 | 2001-02-09 | Procede de criblage d'un agent antiandrogene |
Country Status (4)
Country | Link |
---|---|
US (1) | US20030175817A1 (ja) |
EP (1) | EP1258727A4 (ja) |
AU (1) | AU2001230606A1 (ja) |
WO (1) | WO2001059448A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011132166A (ja) * | 2009-12-24 | 2011-07-07 | Lotte Co Ltd | 抗アンドロゲン剤及び皮脂分泌抑制剤 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296625A2 (en) * | 1987-06-26 | 1988-12-28 | Kabushiki Kaisha Vitamin Kenkyusyo | Agent for inhibiting binding of 5 alpha -dihydrotestosterone with androgen receptor as well as process for obtaining same |
JPH0570360A (ja) * | 1991-09-10 | 1993-03-23 | Lion Corp | 抗男性ホルモン剤 |
WO1993006123A1 (en) * | 1991-09-20 | 1993-04-01 | Fred Hutchinson Cancer Research Center | Human cyclin e |
JPH06228142A (ja) * | 1993-02-05 | 1994-08-16 | Lion Corp | プテロカルペン化合物および抗男性ホルモン剤 |
JPH09151196A (ja) * | 1993-07-12 | 1997-06-10 | Kyowa Hakko Kogyo Co Ltd | トリテルペン酸誘導体 |
WO1997040378A1 (en) * | 1996-04-19 | 1997-10-30 | Vereniging Het Nederlands Kanker Instituut | Interaction of cyclin d1 and estrogen receptor and its use in assays |
WO1997049709A1 (en) * | 1996-06-27 | 1997-12-31 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
JPH11255651A (ja) * | 1998-03-09 | 1999-09-21 | Maruzen Seiyaku Kk | アンドロゲン受容体結合阻害剤 |
JP2000001432A (ja) * | 1998-06-12 | 2000-01-07 | Dai Ichi Seiyaku Co Ltd | アンドロゲン受容体結合阻害剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19810193A1 (de) * | 1998-03-10 | 1999-09-16 | Hilti Ag | Bohrwerkzeug |
-
2001
- 2001-02-09 US US10/203,568 patent/US20030175817A1/en not_active Abandoned
- 2001-02-09 AU AU2001230606A patent/AU2001230606A1/en not_active Abandoned
- 2001-02-09 WO PCT/JP2001/000936 patent/WO2001059448A1/ja not_active Application Discontinuation
- 2001-02-09 EP EP01902829A patent/EP1258727A4/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296625A2 (en) * | 1987-06-26 | 1988-12-28 | Kabushiki Kaisha Vitamin Kenkyusyo | Agent for inhibiting binding of 5 alpha -dihydrotestosterone with androgen receptor as well as process for obtaining same |
JPH0570360A (ja) * | 1991-09-10 | 1993-03-23 | Lion Corp | 抗男性ホルモン剤 |
WO1993006123A1 (en) * | 1991-09-20 | 1993-04-01 | Fred Hutchinson Cancer Research Center | Human cyclin e |
JPH06228142A (ja) * | 1993-02-05 | 1994-08-16 | Lion Corp | プテロカルペン化合物および抗男性ホルモン剤 |
JPH09151196A (ja) * | 1993-07-12 | 1997-06-10 | Kyowa Hakko Kogyo Co Ltd | トリテルペン酸誘導体 |
WO1997040378A1 (en) * | 1996-04-19 | 1997-10-30 | Vereniging Het Nederlands Kanker Instituut | Interaction of cyclin d1 and estrogen receptor and its use in assays |
WO1997049709A1 (en) * | 1996-06-27 | 1997-12-31 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
JPH11255651A (ja) * | 1998-03-09 | 1999-09-21 | Maruzen Seiyaku Kk | アンドロゲン受容体結合阻害剤 |
JP2000001432A (ja) * | 1998-06-12 | 2000-01-07 | Dai Ichi Seiyaku Co Ltd | アンドロゲン受容体結合阻害剤 |
Non-Patent Citations (6)
Title |
---|
ACTA UROLOGICA JAPONICA, vol. 46, no. 10, October 2000 (2000-10-01), pages 763 - 767 * |
DATABASE BIOSIS [online] XP002938972, Database accession no. 200000419486 * |
DATABASE BIOSIS [online] XP002938973, Database accession no. 200100079654 * |
J. CELL. BIOLOGY, vol. 150, no. 4, August 2000 (2000-08-01), pages 873 - 879 * |
KAREN E. KNUDSEN ET AL.: "D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability", CANCER RES., vol. 59, no. 10, 1999, pages 2297 - 2301, XP002938974 * |
See also references of EP1258727A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011132166A (ja) * | 2009-12-24 | 2011-07-07 | Lotte Co Ltd | 抗アンドロゲン剤及び皮脂分泌抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1258727A4 (en) | 2007-02-21 |
US20030175817A1 (en) | 2003-09-18 |
EP1258727A1 (en) | 2002-11-20 |
AU2001230606A1 (en) | 2001-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11766471B2 (en) | Compositions and methods for induced brown fat differentiation | |
JP2005503131A (ja) | Rizに関するスクリーニング、診断および治療の方法 | |
JP2007526913A (ja) | ステロイド依存性の遺伝子活性化経路の異なる段階を標的とする阻害剤の組み合わせによる抗アンドロゲン活性の増強およびその使用 | |
AU2001290179B2 (en) | Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein | |
JP2008537481A (ja) | Gタンパク質シグナリングを阻害する組成物及び方法 | |
EP0887081B1 (en) | Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy | |
US20070020266A1 (en) | Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases | |
WO2001059448A1 (fr) | Procede de criblage d'un agent antiandrogene | |
EP1544295A1 (en) | Salt-inducible kinases 2 and use thereof | |
AU2002230466A1 (en) | Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors | |
Ando et al. | Identification of protein kinase A signalling molecules in renal collecting ducts | |
Lee et al. | MAP, a protein interacting with a tumor suppressor, merlin, through the run domain | |
JP2003520803A (ja) | ホルモンレセプターの調節 | |
US20050142634A1 (en) | Novel modulator of non-genomic activity of nuclear receptors (mnar) and uses thereof | |
AU2006241710B2 (en) | Method for identification of compound having antidepressant effect | |
EP2151452A1 (en) | Bag-1 peptide that inhibits prostate cancer | |
Wang et al. | Molecular mechanism (s) of action of isoproterenol on the expression of the angiotensinogen gene in opossum kidney proximal tubular cells | |
JP3759899B2 (ja) | 新規ヒトアンドロゲンレセプター変異体 | |
US20060105344A1 (en) | Modulation of deubiquitinase family members | |
JP2002506437A (ja) | 癌の新規な検出および治療方法 | |
Ting | The cloning and characterization of androgen receptor coregulators, supervillin and gelsolin | |
Giangrande et al. | Human Progesterone A-Form as a Target for new Drug Discovery in Human Breast Cancer | |
US20050244829A1 (en) | Method of screening insulin resistance inproving drug | |
US20030055225A1 (en) | Monoclonal antibody for the detection of protein products of the brx gene, and uses thereof | |
Horowitz | Role of Nuclear Receptor Coregulators in Hormone Resistant Breast Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 558727 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001902829 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001902829 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10203568 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001902829 Country of ref document: EP |